Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

Koutsounas I, Giaginis C, Theocharis S.

World J Gastroenterol. 2013 Feb 28;19(8):1173-81. doi: 10.3748/wjg.v19.i8.1173. Review.

2.

Current evidence for histone deacetylase inhibitors in pancreatic cancer.

Koutsounas I, Giaginis C, Patsouris E, Theocharis S.

World J Gastroenterol. 2013 Feb 14;19(6):813-28. doi: 10.3748/wjg.v19.i6.813. Review.

3.

An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.

Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C.

Curr Cancer Drug Targets. 2012 May;12(4):439-52. Review.

PMID:
22309455
4.

Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.

Feng W, Zhang B, Cai D, Zou X.

Cancer Lett. 2014 Jun 1;347(2):183-90. doi: 10.1016/j.canlet.2014.02.012. Epub 2014 Feb 15. Review.

PMID:
24534202
5.

Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.

Damaskos C, Karatzas T, Nikolidakis L, Kostakis ID, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A, Kouraklis G.

Anticancer Res. 2015 Jun;35(6):3129-35. Review.

PMID:
26026072
6.

Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.

Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B, Ouaissi A.

J Biomed Biotechnol. 2011;2011:315939. doi: 10.1155/2011/315939. Epub 2010 Oct 25. Review.

7.

Histone deacetylase inhibitors in hematological malignancies and solid tumors.

Chun P.

Arch Pharm Res. 2015 Jun;38(6):933-49. doi: 10.1007/s12272-015-0571-1. Epub 2015 Feb 5. Review.

PMID:
25653088
8.

Recent advances in histone deacetylase targeted cancer therapy.

Hoshino I, Matsubara H.

Surg Today. 2010 Sep;40(9):809-15. doi: 10.1007/s00595-010-4300-6. Epub 2010 Aug 26. Review.

PMID:
20740342
9.

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.

Rangwala S, Zhang C, Duvic M.

Future Med Chem. 2012 Mar;4(4):471-86. doi: 10.4155/fmc.12.6. Review.

PMID:
22416775
10.

Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?

Petta V, Gkiozos I, Strimpakos A, Syrigos K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):935-52. doi: 10.1007/s00280-013-2223-9. Epub 2013 Sep 14. Review.

PMID:
24036844
11.

Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.

Slingerland M, Guchelaar HJ, Gelderblom H.

Anticancer Drugs. 2014 Feb;25(2):140-9. doi: 10.1097/CAD.0000000000000040. Review.

PMID:
24185382
12.

Histone deacetylases and epigenetic therapies of hematological malignancies.

Mercurio C, Minucci S, Pelicci PG.

Pharmacol Res. 2010 Jul;62(1):18-34. doi: 10.1016/j.phrs.2010.02.010. Epub 2010 Feb 26. Review.

PMID:
20219679
13.

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Mottamal M, Zheng S, Huang TL, Wang G.

Molecules. 2015 Mar 2;20(3):3898-941. doi: 10.3390/molecules20033898. Review.

14.

Targeting histone deacetylases in pancreatic ductal adenocarcinoma.

Schneider G, Krämer OH, Fritsche P, Schüler S, Schmid RM, Saur D.

J Cell Mol Med. 2010 Jun;14(6A):1255-63. doi: 10.1111/j.1582-4934.2009.00974.x. Epub 2009 Nov 19. Review.

15.

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.

Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A.

Clin Transl Oncol. 2008 Jul;10(7):395-8. Review.

PMID:
18628067
16.

Histone deacetylase inhibitors: biology and mechanism of action.

Mehnert JM, Kelly WK.

Cancer J. 2007 Jan-Feb;13(1):23-9. Review.

PMID:
17464243
17.

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

Gryder BE, Sodji QH, Oyelere AK.

Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3. Review. Erratum in: Future Med Chem. 2012 Jun;4(10):1369-70.

18.

Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.

Zafar SF, Nagaraju GP, El-Rayes B.

Expert Opin Ther Targets. 2012 Jul;16(7):707-18. doi: 10.1517/14728222.2012.691473. Epub 2012 May 24. Review.

PMID:
22621256
19.

Epigenetic therapy of cancer with histone deacetylase inhibitors.

Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC.

J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937. Review.

20.

New and emerging HDAC inhibitors for cancer treatment.

West AC, Johnstone RW.

J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2. Review.

Items per page

Supplemental Content

Write to the Help Desk